Faeth Therapeutics (FTH) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OmniAb (OABI) has outperformed Faeth Therapeutics (FTH) over the past year, gaining 176.4% versus a gain of 121.4%. Over five years, OABI leads with a -54.3% price change compared with -83.7% for FTH. OmniAb is the larger company by market cap ($677.5 million vs $661.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTH | OABI |
|---|---|---|
| Share price | $25.61 | $4.66 |
| Market cap | $661.77M | $677.52M |
| 1-day change | +2.77% | +2.19% |
| YTD return | +133.55% | +146.49% |
| 1-year return | +121.39% | +176.36% |
| 5-year return | -83.67% | -54.26% |
| EPS (TTM) | $-60.86 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $42.14 | $5.43 |
| 52-week low | $7.45 | $1.30 |
| Distance from 52-week high | -39.23% | -14.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.28% | +88.84% |
| Average volume | 351.88K | 1.45M |
| Shares outstanding | 25.84M | 145.39M |
| Employees | 29 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed FTH by 55.0 percentage points over the past year.
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
FTH vs OABI FAQ
Which is bigger, Faeth Therapeutics or OmniAb?
OmniAb (OABI) is larger, with a market capitalization of $677.52M compared with $661.77M for Faeth Therapeutics (FTH).
Which stock has performed better over the past year, FTH or OABI?
OABI returned +176.36% over the past 12 months, compared with +121.39% for FTH (price return, excluding dividends). Past performance does not predict future results.
Are Faeth Therapeutics and OmniAb in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Faeth Therapeutics and Biotechnology: Commercial Physical & Biological Resarch for OmniAb.